STAAR Surgical announces FDA IDE clinical study approval.
STAAR Surgical announced that the FDA, in a letter dated August 23, stated that it has determined that STAAR has provided sufficient data to support initiation of a human clinical study in the United States of the EVO/EVO+ VISIAN Implantable Collamer Lens for Myopia, and EVO/EVO+ VISIAN Toric Implantable Collamer Lens for Myopia with Astigmatism. FDA also recommended study design modifications, which STAAR plans to incorporate into the investigational plan in a revised submission in the coming month. STAAR's current plan for the study reflects FDA's recommendations from on-going interactive dialogue regarding the investigational protocol, including 300 subjects with a primary endpoint at six months follow up. Subjects enrolled in the trial will not undergo planned peripheral iridotomies. "Finalizing the Investigational Device Exemption, or IDE, with the FDA is an important step towards the future availability of the EVO Visian ICL family of products in the U.S."
|Printer friendly Cite/link Email Feedback|
|Date:||Aug 27, 2019|
|Previous Article:||Ionis Pharmaceuticals licenses hepatitis B program to GlaxoSmithKline.|
|Next Article:||j2 Global division acquires BabyCenter from Johnson & Johnson.|